Advantage of delayed whole-body FDG-PET imaging for tumour detection

被引:225
|
作者
Kubota, K
Itoh, M
Ozaki, K
Ono, S
Tashiro, M
Yamaguchi, K
Akaizawa, T
Yamada, K
Fukuda, H
机构
[1] Tohoku Univ, Dept Nucl Med & Radiol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan
[2] Sendai Kosei Hosp, Sendai, Miyagi, Japan
[3] Tohoku Univ, Ctr Cyclotron & Radioisotope, Sendai, Miyagi 980, Japan
关键词
fluorine-18; fluorodeoxyglucose; positron emission tomography; tumour detection; delayed imaging; lung cancer;
D O I
10.1007/s002590100537
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Delayed imaging that coincides with the highest uptake of fluorine-18 fluorodeoxyglucose (FDG) by tumour may be advantageous in oncological positron emission tomography (PET), where delineation of metastasis from normal tissue background is important. In order to identify the better imaging protocol for tumour detection, whole-body FDG-PET images acquired at I h and 2 h after injection were evaluated in 22 subjects, with a post-injection transmission scan at 90 min for attenuation correction. After visual interpretation, tumour uptake [tumour standardised uptake ratio (SUR)], normal tissue uptake (normal SUR) and tumour to background contrast (tumour SUR/normal tissue SUR) were evaluated in the images acquired at I h and at 2 h, Most malignant lesions, including primary lung cancer, metastatic mediastinal lymph nodes and lymphoma lesions, showed higher FDG uptake at 2 h than at 1 h. By contrast, benign lesions, with the exception of sarcoidosis, showed lower uptake of FDG at 2 h than at 1 h. Among normal tissues, the kidney, liver, mediastinum, lung, upper abdomen and left abdomen showed significant falls in FDG uptake from 1 h to 2 h. The lower abdomen, right abdomen and muscles (shoulder and thigh) showed no significant changes. Consequently, malignant lesions of the lung, mediastinum and upper abdomen showed significant increases in rumour to background contrast from 1 to 2 h, Three lesions (two lung cancers and a malignant lymphoma) that were equivocal on I-h images became evident on 2-h images, changing the results of interpretation. All other malignant lesions were detected on l-h images, but were clearer, with higher contrast, on 2-h images. Lesion-based sensitivity was improved from 92% (49/53) to 98% (52/53), and patient-based sensitivity from 78% (14/18) to 94% (17/18), It is concluded that delayed whole-body FDG-PET imaging is a better and more reliable imaging protocol for tumour detection.
引用
收藏
页码:696 / 703
页数:8
相关论文
共 50 条
  • [21] Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer
    Cheran, SK
    Herndon, JE
    Patz, EF
    LUNG CANCER, 2004, 44 (03) : 317 - 325
  • [22] Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET
    Adams, Hugo J. A.
    Kwee, Thomas C.
    Vermoolen, Malou A.
    de Keizer, Bart
    de Klerk, John M. H.
    Adam, Judit A.
    Fijnheer, Rob
    Kersten, Marie Jose
    Stoker, Jaap
    Nievelstein, Rutger A. J.
    EUROPEAN RADIOLOGY, 2013, 23 (08) : 2271 - 2278
  • [23] The Usefulness of Whole Body FDG-PET/CT in Patients with Brain Metastasis
    Nakagawa, Kazuhiko
    Aoyagi, Masaru
    Inaji, Motoki
    Maehara, Taketoshi
    Toriyama, Hideyuki
    Kawano, Yoshihisa
    Tamaki, Masashi
    Nariai, Tadashi
    Ohno, Kikuo
    NEUROLOGICAL SURGERY, 2009, 37 (02): : 159 - 166
  • [24] 18F-FDG-PET/CT of orofacial tumors, a value of whole-body imaging approach
    Ferda, Jiri
    Ferdova, Eva
    Zahlava, Jan
    Walter, Jiri
    Mukensnabl, Petr
    Daum, Ondrej
    Kreuzberg, Boris
    EUROPEAN JOURNAL OF RADIOLOGY, 2010, 73 (02) : 241 - 248
  • [25] Contribution of whole-body 18FDG PET imaging in the management of cervical cancer
    Belhocine, T
    Thille, A
    Fridman, V
    Albert, A
    Seidel, L
    Nickers, P
    Kridelka, F
    Rigo, P
    GYNECOLOGIC ONCOLOGY, 2002, 87 (01) : 90 - 97
  • [26] Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours
    Lassen, U
    Daugaard, G
    Eigtved, A
    Hojgaard, L
    Damgaard, K
    Rorth, M
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (03) : 396 - 402
  • [27] Impact of whole-body MRI and FDG-PET on staging and assessment of therapy response in a patient with Ewing sarcoma
    Furth, C.
    Amthauer, H.
    Denecke, T.
    Ruf, J.
    Henze, G.
    Gutberlet, M.
    PEDIATRIC BLOOD & CANCER, 2006, 47 (05) : 607 - 611
  • [28] Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours
    U. Lassen
    G. Daugaard
    A. Eigtved
    L. Højgaard
    K. Damgaard
    M. Rørth
    European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 396 - 402
  • [29] Whole-body MR Imaging vs. FDG-PET: Comparison of accuracy of M-stage diagnosis for lung cancer patients
    Ohno, Yoshiharu
    Koyama, Hisanobu
    Nogami, Munenobu
    Takenaka, Daisuke
    Yoshikawa, Takeshi
    Yoshimura, Masahiro
    Kotani, Yoshikazu
    Nishimura, Yoshihiro
    Higashino, Takanori
    Sugimura, Kazuro
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2007, 26 (03) : 498 - 509
  • [30] Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma
    Burns, Robert
    Mule, Sebastien
    Blanc-Durand, Paul
    Tofighi, Mojdeh
    Belhadj, Karim
    Zerbib, Pierre
    Le Bras, Fabien
    Baranes, Laurence
    Haioun, Corinne
    Itti, Emmanuel
    Luciani, Alain
    EUROPEAN RADIOLOGY, 2022, 32 (05) : 3085 - 3096